Background: Mathematical models based on kinetics of HIV-1 plasma viremia after initiation of combination antiretroviral therapy (cART) inferred HIV-infected cells to decay exponentially with constant rates correlated to their strength of virus production. To further define in vivo decay kinetics of HIV-1 infected cells experimentally, we assessed infected cell-classes of distinct viral transcriptional activity in peripheral blood mononuclear cells (PBMC) of five patients during 1 year after initiation of cART
Background
Current combination antiretroviral therapy (cART) does not attack virus-infected cells themselves but targets viral replication at major steps in the viral life cycle [1] . Thus, the decline of HIV-1 plasma viremia induced by cART has been interpreted to reflect cell-specific decay rates of HIVinfected cells with different life-spans and rates of virus production [2, 3] : A first phase of decay, perceptible within the first weeks of cART, has been attributed to the initial loss of productively infected activated T-lymphocytes. Due to their intrinsically short life-span [4] and to direct viral and immunity-mediated cytopathic effects [5] , these cells are prone for rapid cell-death.
Later phases of decay were thought to reflect expanded life-spans of virus producing macrophages or memory Tlymphocytes [5] . In addition, latently infected cells reactivated to productivity, may also contribute to the pool of HIV-virions observed in later decay phases [2, 3] . When viremia levels fall below the threshold of detection, persisting infection is primarily due to a long lived reservoir of latently infected CD4 + cells [6] [7] [8] .
Mathematical models based on plasma viremia only indirectly allow inferring kinetics of latently infected cells which lack virus production. Direct quantification of latently infected cells ex vivo has commonly been attained by viral outgrowth assays of resting CD4 + -T-lymphoctyes [6] . These bioassays relying on inducibility and longevity of donor and indicator cells may underestimate numbers of latently infected cells. Accordingly, their frequencies during cART have been estimated to be very low, in the order of 1 in 10 6 lymphocytes [8] . Further characterization of the cells constituting the latent reservoirs has revealed that only a very low percentage of resting CD4 T-cells carrying HIV-DNA can be induced ex vivo to give rise to viral transcription [9] or antigen production [10] .
This contrasts with comparatively high levels of cell-associated viral RNA (hundreds to thousands of viral RNA copies/10 6 cells) observed in peripheral blood of patients on cART, even in the absence of detectable plasma viremia [11] [12] [13] [14] . Recently, evidence has accumulated that HIV-RNA persisting during cART may to a large extent reflect basal transcription in latently infected cells devoid of virion production [9, 12, [15] [16] [17] . Such bulk measurements of cellular HIV-1 RNAs, despite their potential to monitor viral activity far beyond undetectable viremia [15] , have considerable shortcomings, namely their lack of unambiguous differentiation between viral transcription in latently versus productively infected cells.
In the present study we refined the analysis of HIV-transcription, by combining highly sensitive PCR assays for a panel of unspliced (UsRNA) and multiply spliced (MsRNA) HIV-RNA species with limiting dilution endpoint analysis of PBMC. Using this approach, we were able to dissect the population of HIV-RNA + PBMC according to their level of viral transcription and to determine frequencies and kinetics of cells expressing proviral DNA at different rates.
Results

Analysis of HIV-1 transcription in serial dilutions of PBMC
Individually adjusted RT-PCR targeting HIV-1 nucleic acids was performed on serial dilutions of PBMC assessing HIV-DNA, UsRNA, total MsRNA and MsRNA-tatrev or MsRNA-nef [15] . In parallel to testing total RNA extracts, vRNA-ex representing cell-associated viral particles, was quantified in separate replicate specimens [12, 18] . Limiting dilution analysis of HIV-RNA + cells was performed to compute their frequencies which also allowed determining the average per-cell expression of HIV-RNA.
As shown in figure 1A , the numbers of cells expressing UsRNA or MsRNA experienced significant decreases (p = 0.0006) as a result of antiretroviral treatment while decrease of total HIV-infected PBMC was less pronounced (p = 0.14). Paired analysis throughout the course of observation (one-way Anova-Friedman test, comparison of frequencies of HIV-DNA + , UsRNA + , MsRNA + , vRNA + cells per patient and per time-point; p < 0.0001) showed that total HIV-infected PBMC exceeded cells expressing viral RNA, which revealed a preponderance of transcriptionally silent provirus in peripheral blood. Moreover, cells expressing UsRNA were invariably more frequent than cells expressing MsRNA and the latter were more frequent than cells positive for UsRNA-ex. These findings provide evidence for the existence of cells expressing solely UsRNA and cells expressing MsRNA and presumably also UsRNA and a third very rare population of cells positive for vRNAex.
To further characterize HIV-RNA expression, average intracellular per-cell expression of UsRNA and MsRNA was calculated by normalizing RNA copy numbers to frequencies of total HIV-infected PBMC (figure 1B) or to cells actually expressing viral RNA ( figure 1C ). Using either mode of calculation, per-cell expression of MsRNA was significantly lower in samples obtained during cART as compared to samples from untreated patients (total cells: 4-fold decrease; p = 0.002; figure 1B, HIV-RNA + cells 9-fold decrease; p = 0.0004; figure 1C ). Reduction of percell UsRNA-expression during treatment attained high statistical significance when normalized to total HIVinfected PBMC (20-fold; p < 0.0001; figure 1B) but was perceptible only as a trend when UsRNA-expression was normalized to UsRNA + cells (1.2-fold, p = 0.14; figure  1C ). Thus, per-cell MsRNA expression and to a lesser extent also UsRNA-expression appeared to split up into two discernible states. From these findings the following implications can be inferred: i) Several classes of HIV-infected cells differing in their viral transcriptional activity co-occur before therapy. After initiation of cART cells with lower RNA content appear to outlast cells expressing higher levels of viral RNA.
ii) Three cell classes can be dissected directly using limiting cell-dilution, by virtue of their hierarchical distribution of frequencies: a class which expresses solely UsRNA, one class expressing MsRNA and presumably also UsRNA and a class of cells positive for vRNA-ex.
iii) Cells expressing MsRNA may host one or more subcategories of infected cells with lower and higher viral transcriptional activity.
A model for stratification of viral RNA content in HIV-1 infected PBMC To account for the observed complexity of HIV-RNA expression in PBMC, we designed a simple model to resolve and identify cell categories of different transcriptional states. In particular, the data presented above suggest the coexistence of four main classes of HIV-RNA + cells namely, I Low (low transcriptional activity), II Medium (intermediate transcriptional activity), II High (high transcriptional activity) and III Extra (ongoing extracellular virion shedding).
I Low
HIV-1 infected cells containing solely UsRNA. The existence of this cell class is deduced from our observations that UsRNA-positive cells were invariably more frequent than cells expressing MsRNA.
II Medium
HIV-1 infected cells expressing MsRNA at low levels. Evidence for this class of cells is based on significant differences in per-cell MsRNA content in PBMC from patients on cART as compared to untreated patients. It is highly likely that such cells express UsRNA because MsRNAs are obligatorily derived from primary unspliced HIV-transcripts [19] . [12] . Plasma viremia during one year of cART showed a two phase decline with an initial half-life (mean ± sem, days) of 1.6 ± 0.2 d and a second phase with a half-life of 8.1 ± 2.3 d and suppression of viremia predominantly below levels of 50 RNA copies/ml after 12 weeks of treatment ( figure 4A ). The fact that plasma viremia of patients 111 and 112 were slightly elevated at study week 48 was not considered a therapy failure, since plasma viremia returned to levels below 50 copies/ml at the next visit and remained suppressed during treatment for a further year (data not shown).
II
Kinetics of HIV-1 infected PBMC during cART
Whereas the total number of HIV-1 infected cells, as assessed by HIV-1 DNA levels, experienced comparably modest (74 ± 7%) and slow (t 1/2 = 71 ± 60 d) decreases, in general more than 90% of HIV-1 RNA + cells decayed rapidly after therapy initiation. HIV-infected cell categories of elevated transcriptional activity (class II High , class-III Extra ) became frequently undetectable after initiation of cART. However, their overall kinetics did not unequivocally match plain single phase exponential decay. figure 4G ). Furthermore, contribution of class-II High to total cellular viral RNA burden ( figure  4H ) decreased from 44% at baseline to 30% during the initial month of therapy and declined to <10% by study week 24. Thus class-I Low and class-II Medium cells dominated the population of HIV-infected cells both in terms of cellnumbers as well as in regards to total cellular viral RNA burden.
Outline of experimental strategy
Discussion
In the present study highly sensitive, patient matched quantification of HIV-1 transcripts in total PBMC was combined with endpoint analysis at a single cell level. This enabled us to extend a previous analysis [22] , in which we have observed that the vast majority of infected CD4-positive T-lymphocytes in peripheral blood in vivo expressed viral RNA at levels insufficient for virus production and could therefore be viewed as being of a latent phenotype. Conversely, virus production appeared to be [15, 22] since virion production may likely be precluded in these cells due to their low viral RNA content [15, 22] and because these viral transcripts may potentially be confined to the nucleus [17] .
Class-I Low viral RNA expression remained unchanged in a comparison of specimens from treated and untreated patients. Similarly, class-II Medium HIV-RNA content appeared constant throughout the course of therapy, whereas viral RNA expression of class-II High cells was significantly different in specimens before and during ART. This suggests that a highly active subgroup in this stratum was present in the absence of treatment which conceivably was identical or overlapping with the productively infected class-III Extra .
The stratification of viral RNA expressing PBMC as exercised in the present study provided only an approximate categorical model for the continuous patterns of HIV-1 B Distinction between residual and significant viral RNA content was based on the following rationale: At the endpoint of dilution series of infected cells, specimens containing cells with viral RNA content close to one copy per cell will give PCR-positive readout only in single replicates with considerable variations in ct-values. These data were censored to one copy per specimen as described in Methods. Conversely PCR-readouts ≥ 2 copies/specimen reflect measurements where quantification has been found to be reliable in this dataset.
transcription likely occurring in vivo. Furthermore, it is well possible that the cell classes characterized by different cell-frequencies and viral transcriptional activity may not reflect totally distinct and independent populations of infected cells. Rather they may represent cells 'caught' in different stages of the viral gene life cycle (figure 5, discussed further below) [24] [25] [26] [27] [28] .
Notwithstanding the mathematical-model based nature of our analysis, and the considerable overlap observed in different classes of infected cells, we found good agreement of our results with independent estimates of HIV-1 RNA expression as employed by Haase and colleagues [29] [30] [31] [32] [33] who utilized sophisticated in situ hybridization to asses HIV-transcription ex vivo in lymphoid tissue. In particular they described two types of HIV-RNA + cells which persist during cART with viral RNA content of ≤ 5 copies [32, 33] and cells expressing around 20 RNA copies [30] . These cell-types appear congruent to class-I Low cells and class-II Medium expressing on average 3.7 and 15 HIV-RNA copies/cell respectively. Furthermore, productively HIVinfected cells were estimated to contain on average 50-100 viral RNA-copies in lymphoid tissues whereas average levels of around 1000 RNA-copies were reported for virus producing PBMC cultures [29, 32] . This is highly reminiscent of our observations that class-II High cells, which subsume at least two subcategories, displayed average expression levels of ~330 HIV-RNA copies/cell, which Figure 3 Transcriptional signatures in HIV-infected PBMC in vivo. Per-cell viral RNA expression levels as calculated after assignment of specimens to the transcriptional classes I Low , II Medium and II High ( Class:
Transcriptional signatures in HIV-infected PBMC in vivo
were found to be elevated up to 846 copies/cell at baseline.
All four HIV-RNA + cell categories identified in the current report showed rapid initial declines upon initiation of cART. For cells of high transcriptional activity, this was in concord with the notion that productively infected cells may be associated with the 1 st phase decay of plasma viremia [3] . Indeed, the decay of class-III Extra cells proceeded rapidly and their average half-live (1.5 ± 0. 
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for longer time periods presumably due to moderate expression of viral antigens as predicted by mathematical models based on kinetics of plasma viremia [2, 3] .
Markedly contrary to initial expectations, class-I Low and class-II Medium kinetics proceeded similar to the course of class-II High cells. Whereas it was anticipated that they would show slow but steady exponential decline [2] , we observed substantial initial decays with average half-lives of three to four days which were then followed by persistence. Rapid initial decay of latently infected cells had been previously observed in two reports by Blankson et al [34] and Strain et al [35] in which CD4 + T-cells from acutely infected patients were examined by viral outgrowth A HIV-1 + cells/10 6 PBMC B Decay half-lives were calculated assuming one phase exponential decay to a plateau according to the equations; N t = (N 0 -N P ) × e -Kt + N P ; t = time (days), N 0 = Cell number at baseline; N P = Cell number at plateau; N t = Cell number at time t; T 1/2 = LN(0.5)/(-K). Decay constants were constrained between 0 and 1, to exclude decay half-lifes shorter than 0.7 days to account for the limited data points available during periods of initial decay C Mean ± standard error (sem) of data from all five patients. D Exact determination by fitting of class III Extr could only be achieved for patients 103 and 104 for which minimally three data-points above detection threshold were available. Half-lives of patients 110, 111 and 112 with one or two data points above threshold were estimated as 0.7 days (K = 1).
A model of the turnover of HIV-RNA+ cells during the viral life-cycle [24, [43] [44] [45] [46] . A: Immune activation can promote post-entry events in resting CD4+ T cells harboring free viral cDNA such as integration and initiation of viral transcription [25, 26, 43] . B: Nonspecific immune activation can induce transcription in latently infected cells [27, 47] and may result in a acceleration of viral replication [15, 45] . C: CD8 T-cell mediated cytoxicity (CTL) [39, 40] and humoral immunity [41] , such as antibody-dependent cellular cytotoxicity (ADCC) and complement effector functions [28] , are prone to attack HIV-1 infected cells expressing viral antigens. D: After initiation of cART, the viral life cycle is slowed primarily by preventing new infections but also by decreasing immune activation which results in decelerated rates of integration, detained induction of latency and reduced immune mediated HIV-specific cytotoxicity (A, B, C). assays. In consideration of the in vivo scarcity of provirus inducible by in vitro outgrowth assays [8] , the cell types studied in these earlier reports may not be totally superposable to the two classes of latently infected cells identified in the present study. Hence, the half-lives calculated in the present analysis (0.7-6.3 days) were generally shorter than those reported by Blankson and colleagues (≥ 6 days). Nevertheless, our observation that two types of HIV-RNA + latently infected cells may shift from rapid to slower decay during the course of antiretroviral treatment appears to hold true also for cell subsets inducible by in vitro outgrowth assays. Such apparent variability in turnover of latently infected cells may be interpreted in two ways:
As discussed for class-II High , also cell-class-I Low and class-II Medium may be heterogeneous in terms of virological subcategories but also in reference to cellular lineage and/or in terms of their current state in the viral life cycle. Thus, class-I Low and class-II Medium may comprise cell-types with rapid turnover and long lived cells. Whereas the latter may be allocated to resting HIV-infected CD4 + T-cells [36] , the main candidates for weakly virus transcribing cells with a short half-life could be newly infected cells in a labile state of preintegration latency [9, 37] .
However, HIV-1 DNA levels, which have been reported to be dominated by nonintegrated molecules in PBMC of untreated patients [38] , showed a much less pronounced decay than HIV-infected cells expressing viral RNA and no correlation with frequencies of class-I Low and class-II Medium cells (Spearman R = 0.26, p > 0.12), which were significantly correlated with each other (Spearman R = 0.67, p < 0.0001). This suggests that HIV-RNA + latently infected cells decayed with different kinetics than the majority of HIV-1 infected cells harboring nonintegrated viral DNA. Thus, the fast turnover of unintegrated HIV-DNA may not entirely account for the rapid initial decay of HIV-RNA + cells.
Therefore it is conceivable that turnover rates of HIV-1 infected cells may be intrinsically variable. In particular, they may be influenced by their cellular and humoral environment, which differs under conditions of cART and during viremia. Attenuation of antigenic stimulation due to cART results in declines of cellular [39, 40] and humoral anti-HIV responses [41] , which may decrease death rates of HIV-infected cells expressing viral antigens. Furthermore, generalized immune-activation by HIV-1 [42] [43] [44] [45] [46] may enhance viral replication itself by facilitating the transition from preintegration to genuine chromosomal proviral integration [37] , or by activation of transcriptionally dormant provirus [47] . By accelerating the turnover of latently infected cells and driving the viral life cycle towards productivity (figure 5), feedback loops of various effects of HIV-1 on infected cells may potentiate viral replication [15, 45] . In consequence of the decline of productively infected cells and of viremia, attenuation of antiviral immunity and systemic immune activation may contribute to the observed mitigation in turnover of latently infected cells.
Conclusion
The present study was highly comprehensive in terms of PCR-targets and sample size despite limitations in patient number and in statistical resolution between different cell classes. Thus, it revealed important novel features of HIV-1 transcription and its relation with viral dynamics in vivo.
In summary, at least four categories of HIV-RNA + cells could be identified and assigned to distinct viral transcription patterns. Among these cell classes, latently infected cells represent the majority of HIV-1 infected PBMC both in the absence of treatment and during cART. This emphasizes the crucial role that latent HIV-1 reservoirs play not only in the maintenance of viral persistence during cART but, as precursors of productively infected cells, also under conditions of ongoing viral replication.
Foremost, we have gained evidence suggesting that at least two types of latently HIV-1 infected cells after initiation of cART decay with kinetics similar to those of productively infected cells. These rapid decays may be shaped by cellular and humoral immune responses against HIV and by HIV-induced activation which prevail before and early after initiation of cART but wither away when viral replication is stably suppressed. Verifying the hypothesis that decay of latently HIV-infected cells may not be constant but prone to influences from their cellular and humoral environment and identifying the factors governing the turnover of latently infected cells may help to devise novel therapeutic strategies to pursue the as yet elusive aim of eradicating HIV-1.
Methods
Patients and specimens
Five chronically HIV-1 infected therapy naïve patients initiating cART according to standard treatment guidelines (patient nr 103, 104, 110, 111, 112) were enrolled after informed consent was obtained. The study was approved by the ethics committee of the University Hospital Zürich. Patients were treated with zidovudine plus lamivudine (300 mg BID), and ritonavir boosted lopinavir (100/400 mg BID), except for patient 103 who replaced ritonavir/ lopinavir by efavirenz (daily 1 × 600 mg) at week 32. Median (range) baseline clinical parameters were 147(116; 262) CD4 T-lymphocytes/μl blood and 158'000 (14'300; 203'500) viral RNA copies/ml plasma. PBMC were purified as described [15] and aliquots (n = 8-14) were distributed into equal proportions ranging from 1-4 million cells/tube. Further serial five-fold dilutions of PBMC (12-24 replicates each; 5×, 25×, 125×, 625×, 3125× dilutions) were prepared and diluted PBMC were supplemented with uninfected CEM cells [48] (3 × 10 5 cells/aliquot) to avert cell loss in dilutions. Cells were stored at -80°C as dry pellets.
Nucleic acid analysis
RNA was extracted (RNeasy, Qiagen Hombrechtikon, CH) using two protocols in parallel [12, 15] . Total PBMC RNA was extracted by the standard procedure [49] and specific isolation of PBMC-associated extracellular, virionenclosed HIV-RNA (vRNA-ex) was performed by nucleolytic digestion of cellular nucleic acids while RNA enclosed in viral envelopes remain protected [12, 15, 18] . RNA was eluted in a volume of 0.1 ml.
PCR primers and fluorescent probes mapping to the gag gene were used to quantify UsRNA, vRNA-ex and HIV-DNA [50] . PCR strategies to quantify viral nucleic acids are shown in figure 6A . Analysis of MsRNA was performed [15] utilizing a PCR for MsRNA encoding Nef, Tat and Rev (MsRNA-total) and an assay for MsRNA encoding Tat and Rev (MsRNA-tatrev). Subtracting copy numbers of MsRNA-total from MsRNA-tatrev allowed for calculation of MsRNA encoding Nef (MsRNA-nef) [15] . Some specimens with very low HIV-RNA content, showed MsRNAtotal copy numbers smaller or equal to MsRNA-tatrev, in this case MsRNA-nef was assumed being undetectable. Since values for MsRNA-tatrev and MsRNA-nef showed similar kinetics, data analysis of the sum of both parameters, referred to as MsRNA, was performed. HIV-1 PCR primers used were individually adjusted to their binding sites for each patient's predominant quasispecies as described [22] (table 3) . Real time RT PCR assays were performed using a protocol which approached single copy sensitivity as previously reported [15, 18, 22] and as exemplified in figure 6B . HIV-DNA was amplified as described [22] . PCR was performed in duplicate reactions using 10-20 μl RNA per specimen. PCR data were interpolated from patient-matched RNA standard-curves [22] . HIV-RNA in plasma was measured using Amplicor HIV-Monitor version 1.5 (Roche Diagnostics, Basel, Switzerland).
Calculations and statistics
Statistics were performed using GraphPad Prism4.0 software (GraphPad Software, San Diego, CA).
RNA copy-numbers were calculated as the mean of duplicate PCR measurements, extrapolated to copy numbers per tube (5-10-fold multiplication) and normalized to the input of PBMC. In HIV-RNA + specimens near the detection limit of the test, quantification of HIV-RNA was censored to avoid gross overestimation: If only one duplicate PCR was positive and/or nominal copy numbers were below 1 copy per reaction, it was assumed that 1 RNA copy had been present per tube.
Stratification and assignment of specimens to different transcriptional classes were executed according to criteria compiled in table 1. Frequencies of HIV-RNA + cells were calculated by 50% endpoint analysis [22] according to the method described by Muench and Reed [51] . Specific RNA contents in different transcriptional classes were calculated by a stepwise "bottom up" approach in which the contribution of the different classes of HIV-RNA expressing cells was dissected as described in figure 2: Since cells of frequent transcriptional classes co-occurred with cells of rarer classes, the contribution of the first had to be subtracted from the total copy numbers to calculate the copy numbers of the latter. After this subtraction HIV-RNA copy numbers in a given specimen were normalized to its content of HIV-RNA + cells. Rarely this resulted in nominally negative values which were censored to 1 copy per cell, to allow further analyses using logarithmic transformation.
Statistical comparisons between groups were performed using nonparametric tests; the Mann-Whitney test for unpaired data-sets, Wilcoxon signed rank tests for paired analyses and, when adjustment for multiple testing was applied, one way Anova and a Friedman post test analyzing all possible combinations was applied.
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HFG participated in conceiving the study, and participated in its design and coordination and helped to draft and finalize the manuscript. All authors read and approved the final manuscript. Figure 6 PCR-Quantification of HIV-RNAs. A: Location of primers and probes used for PCR. Labeled bars depict viral genes and the unlabelled bars below show exons of viral transcripts quantified as previously described [15] . White: genomic RNA spanning the entire transcriptional unit, grey: multiply spliced RNAs encoding tat and rev (dark grey) or nef (light grey). Arrows show the location of PCR primers and barbells the positioning of fluorescent probes. Note that MsRNA-nef was calculated as the difference of copy number for MsRNA-total and MsRNA-tatrev as described previously [15] (formula indicated in italic letters). B: Performance of PCR assays. Patient-specific in vitro transcribed UsRNA and MsRNA prepared from templates isolated from patient 104 and quantified photometrically was subjected to RT-PCR using patient specific primers as listed in table 3. Ten-fold dilutions ranging from 5 × 10 7 -5 copies were run in replicates of two (5 × 10 7 -5 × 10 4 copies) or four (5000-5 copies). Upper panels show amplification plots (mean ± standard error) with the amplification threshold (broken lines) as calculated by default settings of the software used (i-cycler, Biorad). In the lower panels log-transformed copy numbers were plotted against cycle-threshold (ct) values of each replicate. Linear regression analysis as shown by the resulting equations for black lines (broken lines depict 95% confidence intervals) revealed high correlation coefficients of standard curves. PCR efficiencies as deduced from slopes ranged from 89%-96%. Sensitivities of PCR assays (grey vertical lines, italic numbers) were estimated by determination of 50% endpoints [51] . All assays approached single copy sensitivities as previously documented [15, 22] with assays for MsRNA-tatrev (1.6 copies) being the most sensitive ones followed by PCR for UsRNA/vRNA-ex (2.3 copies) and the assay for MsRNA-total (5 copies). PCR assays for the other patients performed similarly (data not shown). 
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